All 1 tracked stories fall under one category: health-it. Of the tracked stories, 1 of 1 also mention Bakkt, the most common co-covered peer. Source depth averages 3 original sources per story, versus 2.5 across the same-window beat baseline. Their average consequence score of 6 runs above the beat's 5.8 for that window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about INO-3107
All 1 tracked stories fall under one category: health-it. Of the tracked stories, 1 of 1 also mention Bakkt, the most common co-covered peer. Source depth averages 3 original sources per story, versus 2.5 across the same-window beat baseline. Their average consequence score of 6 runs above the beat's 5.8 for that window. INO-3107 appears in 1 tracked Healthcare story from March 18, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 24 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering INO-3107. Shared-story counts are live from our verified record — not editorial picks.
Inovio Pharmaceuticals faces a critical regulatory juncture as the FDA accepts its BLA for INO-3107 while questioning its accelerated approval eligibility. Meanwhile, LivePerson is pivoting toward a unified AI architecture with the launch of its Syntrix platform, signaling a shift in how healthcare enterprises may manage patient engagement.